NVO
Novo Nordisk A/S
38.20$
-0.2%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -76.7% | +49.9% | +252.8% | -13.2% | -71.9% | +99.9% | +65.9% | +13.0% | -83.5% | +216.1% | +129.2% | – | |
| – | +18.5% | -2.6% | +203.5% | -75.7% | +141.8% | -26.3% | +26.2% | +60.5% | -28.3% | -36.4% | +191.4% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -183.0% | – | – | -214.3% | – | -220.8% | – | -204.3% | – | -263.1% | – | – | |
| – | +54.7% | -45.2% | +46.9% | -5.5% | +32.4% | -11.9% | +11.6% | -5.3% | +184.4% | -72.5% | +6.3% | – | |
| – | -49.6% | – | -624.0% | +0.8% | +336.4% | -92.7% | +113.5% | +8.3% | +177.5% | -72.6% | +9.0% | – | |
| – | -100.0% | +12,998,434.3% | -100.0% | – | +183.3% | -20.1% | -99.5% | +9,476.4% | -98.5% | +13,650.5% | -100.0% | – | |
| – | +58.9% | -70.9% | +162.7% | -67.7% | +211.5% | -81.5% | -97.1% | +14.4% | -85.3% | +34,753.3% | +45.8% | – | |
| – | – | – | – | – | – | -65.4% | -228.0% | -97.8% | – | -50.0% | -149.8% | – | |
| – | -49.0% | +160.8% | – | -210.3% | – | -85.2% | -948.1% | -63.0% | – | -159.2% | +9.7% | – | |
| – | -286.4% | – | – | -91.0% | -1,085.5% | – | -188.1% | – | -141.2% | – | – | – | |
| – | -122.7% | – | +602.5% | -15.9% | -113.6% | – | +145.0% | +25.2% | -218.0% | – | +252.0% | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.